Merck, a leading science and technology company in healthcare, life science and performance material, today announced the expansion of its ‘M Lab Collaboration Center’ in Bengaluru. The expanded center includes a simulated manufacturing environment and enables collaboration with Merck experts to evaluate processes and accelerates development and production of new therapies, the company said. In addition, education on best practices and new approaches to develop, optimize and scale-up processes and ways to simplify global technology transfer will be available to customers, Merck said in a release here.
The facility will provide biopharmaceutical manufacturers with a shared, exploratory environment where they can closely collaborate with Merck scientists and engineers to solve their toughest challenges and accelerate development of new therapies, it said.”Bangalore is a hub for India’s rapidly growing biopharmaceutical manufacturing industry,” noted Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
You may also like to watch:
With the expansion of M Lab Collaboration Center in Bengaluru, customers are being provided with hands-on experience and customized support to optimize their manufacturing processes to quickly bring much-needed therapies to patients, he said. The new M Lab Collaboration Center in Bengaluru is one of nine such centers around the world. At Merck, around 50,000 employees work to further develop technologies from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions, the release said. In 2016, Merck generated sales of 15.0 billion Euro in 66 countries.
Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company, the release noted.